Table 2. Seroreactivity to MAP, ZnT8 and PI epitopes in different age groups and during insulin independence period.
Percentages of patients positive to the analyzed epitopes are reported along with the relative numbers of seroreactive subjects given in brackets. Mann-Whitney U test was employed to calculate statistical significance.
| Age group (years) | LADA patients | LADA 1 | LADA 2 | HCs | |||
|---|---|---|---|---|---|---|---|
| Onseta | Sample collectionb | Onset | Sample collection | Onset | Sample collection | Sample collection | |
| Abs prevalence for 8 peptides (%) | |||||||
| 32–41 | 34.37 (11) | 32.26 (10) | 40.00(6) | 45.45 (5) | 29.41 (5) | 27.78 (5) | 38.46 (20) |
| 42–51 | 8.51 (4) | 17,78 (8) | 11.11 (2) | 20.00 (4) | 6.89 (2) | 16.00 (4) | 18.46 (12) |
| 52–61 | 25.93 (21) | 21.43 (12) | 25.93(7) | 23.53 (4) | 25.93 (14) | 20.51 (8) | 10.64 (5) |
| >61 | 21.43 (6) | 20.69 (12) | 7.14 (1) | 11.54 (3) | 33.33 (5) | 27.28 (9) | 11.12 (2) |
| Abs prevalence for MAP2404c70-85/PI46-61 (%) | |||||||
| 32–41 | 25.00 (8) | 22.58 (7) | 33.33 (5) | 36.36 (4) | 17.65 (3) | 16.67 (3) | 21.15 (11) |
| 42–51 | 8.51 (4) | 17,78 (8) | 11.11 (2) | 20.00 (4) | 6.89 (2) | 16.00 (4) | 10.77 (7) |
| 52–61* | 23.46 (19) | 17.86 (10) | 25.93 (7) | 23.53 (4) | 22.22 (12) | 15.38 (6) | 6.38 (3) |
| >61 | 21.43 (6) | 20.69 (12) | 7.14 (1) | 11.54 (3) | 33.33 (5) | 27.28 (9) | 0.00 |
| Insulin-free periodc | Abs prevalence for MAP2404c70-85/PI46-61 (%) | ||||||
| ≤12 | 17.39 (4) | - | 14.28 (1) | - | 18.75 (3) | - | - |
| 13–24 | 23.53 (4) | - | 0.00 | - | 33.33 (4) | - | - |
| 25–36 | 18.19 (2) | - | 16.67 (1) | - | 20.00 (1) | - | - |
| 37–48 | 17.10 (13) | - | 18.75 (6) | - | 15.90 (7) | - | - |
| >48 | 14.28 (2) | - | 25.00 (1) | - | 10.00 (1) | - | - |
* Statistically significant.
a Samples collected at the time of LADA diagnosis.
b Samples collected during a control medical visit following LADA onset.
c Expressed in months.